60 day FRN

53376

Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
responses per
respondent

Number of
respondents

Average
burden per
response
(in minutes)

Total burden
hours

Respondent

Form

Cruise ship operator .........................

Attestation statement of COVID–19
free ship (for repatriating crew via
commercial travel).

100

1

20/60

33

Total ...........................................

...........................................................

........................

........................

........................

4,134

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–19010 Filed 8–27–20; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Please note: Submit all comments through
the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.

Centers for Disease Control and
Prevention
[60Day–20–1218; Docket No. CDC–2020–
0091]

Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled ‘‘Evaluation of MedicationAssisted Treatment (MAT) for Opioid
use disorder.’’ CDC will use the
collection to continue the epidemiologic
study to assess the type of MAT
(methadone maintenance;
buprenorphine; naltrexone; or,
counseling, no MAT), and the
contextual, provider, and individual
factors that influence implementation
and improved patient wellbeing.
DATES: Written comments must be
received on or before October 27, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0091 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.

VerDate Sep<11>2014

17:16 Aug 27, 2020

Jkt 250001

To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
FOR FURTHER INFORMATION CONTACT:

Proposed Data Collection Submitted
for Public Comment and
Recommendations

SUMMARY:

• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.

PO 00000

Frm 00060

Fmt 4703

Sfmt 4703

including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
Proposed Project
Evaluation of Medication-Assisted
Treatment (MAT) for Opioid Use
Disorder—Revision—National Center
for Injury Prevention and Control
(NCIPC), Centers for Disease Control
and Prevention (CDC)
Background and Brief Description
CDC seeks a one-year OMB approval
to continue collecting data for
Medication-Assisted Treatment (MAT)
for Opioid use disorder. Approximately
2.4 million people aged 18 or older have
opioid use disorders (OUDs) in the
United States. At any given time, only
half of these people receive some form
of treatment, which may include
medication-assisted treatment (MAT) or
abstinence-based psychotherapy or selfhelp treatments (i.e., counseling without
medication [COUN]). The rise in opioid
overdose deaths, up from 2014–2015
due partly to a 72% rise in synthetic
opioid overdose deaths alone, shows
that engaging and retaining clients in
OUD treatment is an urgent public
health need. Only a few studies are
available to help clients and providers
make informed decisions about the risks
and benefits associated with the
different types of MATs. This
information is crucial because even
though each MAT drug helps prevent
withdrawal symptoms and decreases
cravings, differences in treatment
approach and settings influence how
people respond to the medication and,
thus, their long-term treatment success.

E:\FR\FM\28AUN1.SGM

28AUN1

53377

Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices
The purpose of this study is to
conduct an epidemiologic, mixedmethods evaluation of OUD treatment in
real-world outpatient settings. Client
recruitment for this study was originally
scheduled to take place between 5/1/
2018 and 8/31/2019, however patient
recruitment levels were lower than
originally anticipated. The recruitment
period was extended to 11/30/2019 to
enable to recruit additional patients.
Because the follow-up period for this

such as multilevel latent growth models,
propensity score matching, latent class
analysis and advance mediation
analysis and qualitative methods such
as interactive coding and analysis for
common themes. There are no costs to
respondents other than their time. The
only cost to respondents will be time
spent responding to the survey/screener.
CDC requests approval for 300
annualized burden hours.

study is 18 months, patients recruited
during the extended recruitment period
(8/31/2019 to 11/30/2019) will need to
complete their final 18-Month Patient
Questionnaire between 2/28/2021 and
5/31/2021, which is after the current
OMB expiration date. The extended
time period is only needed for one of
the data collection instruments, thus
there is a reduction in burden of 3839
hours.
The study uses a mixed-method
approach using quantitative methods

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Number of
responses per
respondent

Average
burden per
response
(in hours)

Total
burden
hours

Type of respondent

Form name

Patients .............................................

Client Questionnaire 18-Month Follow-up.

400

1

45/60

300

Total ...........................................

...........................................................

........................

........................

........................

300

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–18997 Filed 8–27–20; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–20–20QN; Docket No. CDC–2020–
0085]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on ‘‘Availability, Use, and
Public Health Impact of Emergency
Supply Kits among Disaster-Affected
Populations.’’ The goal of this study is
to determine the efficacy and public
health impact of emergency supply kits
among disaster-affected populations to

SUMMARY:

VerDate Sep<11>2014

17:16 Aug 27, 2020

Jkt 250001

understand how emergency supply kits
are used during and after a natural
disaster, if public health outcomes are
associated with access to emergency
supply kits, and what the most useful
items to include in an emergency
supply kit are across different types of
disasters.
DATES: Written comments must be
received on or before October 27, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0085 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to Regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
Please note: All public comment
should be submitted through the
Federal eRulemaking portal
(Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffry Zirger,
Information Collection Review Office,
Centers for Disease Control and

PO 00000

Frm 00061

Fmt 4703

Sfmt 4703

Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,

E:\FR\FM\28AUN1.SGM

28AUN1